Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib (Velcade) combination reinduction in childhood relapsed ALL
2009-014037-25Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Aug 2009
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in acute lymphoblastic leukemia (ALL), sponsored by Erasmus MC. Primary endpoint: Antileukemic activity at day 8. Started Aug 2009; status: completed.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2009-014037-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014037-25.